Convergent Synaptic Collapse (CSC) — Grading Reference
How do independent upstream mechanisms all arrive at one synapse?
The Theory
Alzheimer's disease is a disease of network failure — multiple independent pathogenic mechanisms converge on shared anatomical and molecular nodes, progressively destroying synaptic architecture until cognitive collapse becomes inevitable. No single mechanism is sufficient alone; their convergent, synergistic operation produces neurodegeneration.
The 6 Convergence Nodes
1. Endosomal Nexus — The early endosome as the critical anatomical compartment where pathways converge:
- Lipid peroxidation disrupts receptor trafficking (Ramsden: ApoE-ApoER2-Dab1 pathway)
- Retromer dysfunction creates "endosomal traffic jams" (Small: SORL1, VPS26b)
- Intraneuronal Abeta42 accumulates in MVBs (Gouras: inside-out paradigm)
- APP processing dysregulation generates sequestered Abeta (Huang)
- Key molecules: ApoER2, Dab1, SORL1, VPS26b, BACE1, v-ATPase
2. Cytoskeletal Collapse Node — Actin and microtubule cytoskeleton attacked by multiple mechanisms:
- LIMK1 hyperactivation and cofilin inactivation (Ramsden: GSK3beta cascade)
- Ephexin5-RhoA-ROCK-mediated actin-myosin contraction (Margolis)
- Competitive synaptic plasticity dysregulation (Huang)
- Complement-mediated dendritic spine destruction (Shatz/Brott)
- Key molecules: GSK3beta, LIMK1, cofilin, Ephexin5, RhoA, ROCK, PSD95
3. Compensatory Paradigm Nexus — Hallmark pathological features as initially protective responses:
- Abeta as antioxidant response to lipid peroxidation (Ramsden)
- Abeta/tau as compensatory for excitatory insufficiency (Moosmann: NMDA hypofunction)
- Lipid raft restructuring as allostatic adaptation (Rappoport)
- Abeta monomer depletion drives compensatory overproduction (Huang)
- Key concept: adaptive responses become pathologically reinforced over time
4. Neuroimmune Interface — Microglial-complement pruning cascade:
- C4d deposition on synapses triggers LilrB2 signaling (Shatz/Brott)
- TREM2-mediated microglial phagocytosis of synapses
- Pattern recognition of DAMPs (oxidized proteins, Abeta, pTau)
- Trans-synaptic immune signaling triggers cytoskeletal collapse
- Key molecules: C1q, C3, C4d, LilrB2, TREM2, CR3
5. APOE4 Hub — Single polymorphism activating 8+ pathogenic mechanisms:
- Loss of disulfide bridge = unprotected PUFA cargo = lipid peroxidation
- Impaired retromer function and endosomal trafficking
- Reduced excitatory tone
- Altered lipid raft organization and complement activation
- Promotes Ephexin5-RhoA activation and dendritic spine collapse
- Key concept: simultaneously loss-of-function AND gain-of-function
6. Transcriptional-Epigenetic Dysregulation Node:
- CREB-mediated transcriptional changes from NMDA hypofunction (Moosmann)
- HDAC6 upregulation and chromatin remodeling (Rappoport)
- miRNA dysregulation (miR-134, let-7) affecting spine stability
- LINE-1 transposable element reactivation
- Progressive gene expression changes that lock in pathological state
5-Stage Temporal Model
- Molecular Initiation (Years -30 to -15): Primary insult accumulates (lipid peroxidation, excitatory insufficiency, or Abeta monomer loss). No histopathology yet.
- Endosomal Dysregulation (Years -15 to -5): Compensatory responses become excessive. Abeta accumulates in endosomes. Retromer dysfunction manifests. Asymptomatic but amyloid-positive.
- Cytoskeletal Perturbation (Years -5 to 0): GSK3beta hyperactive, dendritic spines begin collapsing. First cognitive changes. Transition to MCI.
- Neuroimmune Activation (Years 0 to 5): Complement cascade activated, microglial pruning accelerates. Progressive synaptic loss. Mild-to-moderate impairment.
- Network Disintegration (Years 5 to 15): Widespread neuronal death, tau tangles, plaques. Severe dementia.
Grading Scale
| Grade | Label | Meaning |
|---|---|---|
| A | Core Overlap | Hypothesis directly addresses one or more CSC convergence nodes as a primary mechanism |
| B | Supplementary | Provides evidence, data, or mechanisms that feed into CSC nodes without being a central CSC claim |
| C | Adjacent | Operates in a related domain but doesn't directly map to CSC nodes; potential future integration |
| D | Orthogonal | Addresses AD through a mechanism not currently represented in the CSC network |
| X | Contradicts | Makes claims that directly contradict a CSC node or the network model |
Instructions for Grading
- Read the prize entry paper
- Identify the core hypothesis/mechanism proposed
- Map it against the 6 CSC nodes — which nodes does it touch?
- Assign a grade based on the degree of overlap
- Note which specific nodes are relevant
- Write a 1-2 sentence rationale
The Validity Ledger
The argument above is only as strong as its weakest load-bearing joint, and the reader is owed an explicit accounting of where it stands on the ground and where it stands on inference.
Each claim below carries a tier and, where it is not settled, the observation that would settle it. 3 claims · 2 not yet settled
Strong (imported, established) — The early endosome is a critical anatomical compartment in which several of these mechanisms meet.
Endosomal abnormality is among the earliest documented cellular changes in the disease, established in human material before amyloid deposition.
Moderate (inference, the corpus's own frame) — Alzheimer's disease is a disease of network failure in which multiple independent mechanisms converge on shared nodes, and no single mechanism is sufficient alone.
The framework this reference document grades against. Insufficiency of any single mechanism is well supported by the failure of single-target therapy; that convergence is synergistic rather than merely concurrent is the stronger claim and is inferred.
What would settle it. Blocking two convergent mechanisms separately and together, testing for synergy rather than addition.
Weak (predicted, untested) — The six convergence nodes are the right six — complete and non-redundant.
A claim about the taxonomy rather than about the disease. The corpus has already added a seventh axis once, which is itself evidence that the set is provisional.
Genes named on this page: ARHGEF15 (Ephexin5), Ephexin-5, Ephexin5; RhoA; GSK3B, GSK-3β, GSK3β, GSK-3beta, GSK3beta; ApoE, apoe4; TREM2; LilrB2; LRP8 (ApoER2), ApoER2; Dab1; C4 (complement), C4d; SORL1; LIMK1; APP; V-ATPase (ATP6V), v-ATPase; BACE1; C1QA, C1q; C3; CR3; DLG4 (PSD-95), PSD95, PSD-95; HDAC6.